- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04820543
Effects of Dose and Injection Site for Gummy Smile Treatment With Botulinum Type A
Effects of Dose and Injection Site for Gummy Smile Treatment With Botulinum Type A: A Prospective Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The smile is one of universal facial expressions of the humans. Gingival smile (GS) or gummy smile defined as any exposure of the gingiva >2 or 3 mm upon smiling, and can substantially vary from patient to patient, with patients presenting gummy exposures of up to more than 10 mm. The prevalence of GS is 10.57%, and it is more frequently seen in women. Although only an anatomical variation, it can be considered unattractive and cause significant distress and impact on one's quality of life. Moreover, most orthodontists and dentists regard GS as an important risk factors for dental treatment.
GS involves a complex interaction of facial muscles, bones and skin, specifically, it is related to the hypermobile upper lip (HUL) by the involved muscles and alterations in anatomical features such as short clinical dental crown, anterior dentoalveolar extrusion, maxillary excess and short upper lip. Therapies for GS range from botulinum toxin injections to surgical interventions according to its etiology. Whereas the outcomes of surgical procedures are long-lasting, botulinum toxin type A (BTX-A) treatment is an easy and fast outpatient procedure, requiring no downtime and with high efficacy rates. Nevertheless, there are controversies on the dosage and injection sites of BTX-A, and the efficiency of BTX-A for GS treatment shows great variation in different studies, with the improvement rate of gingival exposure (GE) ranging from 62.06% to 98%, Sucupira and Abramovitz advocate the use of an average amount of BTX-A of 2 U at bilateral levator labii superioris alaeque nasi muscles(LLSAN) for the treatment of GS, and an average satisfaction level of 9.75 on a 10-point scale was noted in their study. In their article, use of larger dosages and additional injection sites is discouraged: "Other target muscles described in the literature do not give any additional benefit to this application and could easily lead to lip ptosis, inferior lip protrusion, asymmetry, or excessive lengthening of the upper lip." Polo disagreed their argument. They believe that dosage and injection sites of BTX-A need to be individualized according to the degree of severity presented. However, no clinical study compared and verified their divergence, and the highly personal experience and uncertainty still limit the use of BTX-A for GS treatment. Some authors are of the opinion that injection with BTX-A is a safe and cosmetically effective treatment for GS only when performed by experienced practitioners. Other studies preferred to initiate the treatment with average-dose BTX-A injection to single sites initially, with retouching at a later stage, as and when required. Based on the lack of studies at the stage of creating the hypothesis for this study, the investigators compared the efficiency using the simplified method use of 2U BTX-A of at bilateral LLSAN and the individualized injection of dosage and injection sites according to the severity of anterior GS presented in patients, and also to assess safety and patients' satisfaction with the treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100010
- Peking University School and Hospital of Stomatology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ≥ 3.0-mm anterior gingival exposure upon unrestricted, "full-blown" smiling
- healthy adults
Exclusion Criteria:
- contraindication of BTX-A
- previous diseases or treatments affecting the position of the gingiva or upper lips
- history of BTX-A injections to the head or neck region
- facial paralysis
- having received and/or receiving active orthodontic treatment that includes vertical dimension treatment, such as extrusion and intrusion, and presence of periodontal disease
- subject's refusal to participate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Simplified Method
In this method, a uniform BTX-A injection technique with single-site injection of 2 U BTX-A (total, 4 U) at both right and left levator labii superioris alaeque nasi muscles (LLSAN) was administered.
The injection points located at the muscle bulge at the uppermost part of the nasolabial fold.
|
The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later.
All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution.
The injections were made with a 27-gauge insulin syringe.
The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.).
No anesthesia was given during the procedure.
Other Names:
|
Experimental: Individualized Method
In this method, the patients were administered BTX-A after 8 months when the effect of the previous injection vanished.
And A dosage and injection sites were individualized according to the degree of severity of anterior GE presented pretreatment.
For mild GS (3 to< 5mm), 2 U BTX-A was injected at bilateral LLSAN.
For moderate (5 to < 7mm) and severe GS (≥ 7mm), 3 U and 5 U of BTX-A were injected per side (total, 6 U and 10U).
And The injection points located at both LLSAN and the Yonsei point, with half doses at each point.
|
The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later.
All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution.
The injections were made with a 27-gauge insulin syringe.
The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.).
No anesthesia was given during the procedure.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
anterior gingival exposure (GE)
Time Frame: 4 weeks postinjection
|
The distance from the superior margin point of the right incisor to the lower margin of the upper lip upon maximum smile.
|
4 weeks postinjection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
bilateral posterior GE
Time Frame: 4 weeks postinjection
|
The distance between the superior margin point of the right first premolars, the left first premolars and the lower margin of the upper lip, respectively.
|
4 weeks postinjection
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- pkussGS2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Botulinum Toxins, Type A
-
Peking UniversityCompletedBotulinum Toxins, Type A | SmilingChina
-
Peking UniversityCompletedBotulinum Toxins, Type A | SmilingChina
-
Loma Linda UniversityAllerganCompletedMuscle Strength | Botulinum Toxins, Type AUnited States
-
Universidad Autonoma de Nuevo LeonCompletedPlantar Fascitis | Botulinum Toxins, Type AMexico
-
Region VästerbottenUmeå University; Mahidol UniversityCompletedBotulinum Toxins, Type A | Bite ForceSweden
-
Buddhist Tzu Chi General HospitalCompletedBotulinum Toxins, Type ATaiwan
-
Shanghai Jiao Tong University School of MedicineCompletedBotulinum Toxin, Type A
-
Cairo UniversityCompletedProstatic Hyperplasia | Ultrasonography | Male | Botulinum Toxins, Type A | Injection; Complications, InfectionEgypt
-
The University of Hong KongFood and Health Bureau, Hong KongCompletedHemifacial Spasm | Blepharospasm | Botulinum Toxins, Type A
-
DynPort Vaccine Company LLC, A GDIT CompanyCompletedRECOMBINANT BOTULINUM VACCINE A/BUnited States
Clinical Trials on injection of Botulinum type A
-
Evolus, Inc.CompletedGlabellar Frown LinesUnited States
-
Peking UniversityCompletedBotulinum Toxins, Type A | SmilingChina
-
HugelCompletedBenign Masseteric HypertrophyKorea, Republic of
-
Khon Kaen UniversityUnknown
-
HugelCompletedOveractive BladderKorea, Republic of
-
HugelCompletedCervical DystoniaKorea, Republic of
-
AllerganTerminatedOveractive BladderSerbia, Turkey, Greece, Egypt, Lebanon, India
-
HugelRecruitingGlabellar LinesKorea, Republic of
-
Seton Healthcare FamilyCompleted
-
HugelCompletedGlabellar LinesKorea, Republic of